Drug Profile
Research programme: amyotrophic lateral sclerosis therapeutics - reMYND
Latest Information Update: 17 Jul 2023
Price :
$50
*
At a glance
- Originator reMYND
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Amyotrophic lateral sclerosis
Most Recent Events
- 17 Jul 2023 Research programme: amyotrophic lateral sclerosis therapeutics is still in research phase for Amyotrophic lateral sclerosis in Belgium (reMYND Pipeline, July 2023)
- 28 Aug 2020 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in Belgium
- 21 Jul 2016 Early research in Amyotrophic lateral sclerosis in Belgium (unspecified route)